vin 2012 - pellegrino on ecmo
DESCRIPTION
VIN Pellegrino talks ECMO at the VIN Meeting 2012TRANSCRIPT
![Page 1: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/1.jpg)
Advancing Circulatory Care
(2012 - )Vincent Pellegrino
Victorian Intensive Care NetworkAugust2012
![Page 2: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/2.jpg)
Choice
![Page 3: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/3.jpg)
Before I start......
![Page 4: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/4.jpg)
1992: First ICU Rotation
• 1800-0800 (14 beds) RMO only cover
• Closed loop control of circulation
• Open loop control of feeding
• Open loop control of tonicity
![Page 5: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/5.jpg)
![Page 6: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/6.jpg)
1992: First ICU Rotation
J Crit Care (1994) 9: 124-133
![Page 7: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/7.jpg)
1992: First ICU Rotation
J Crit Care (1994) 9: 124-133
10 Patients APII 30
CRRT-HF601 hour
417 (L) lost409 (L) administered
3 survived (hosp discharge)
![Page 8: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/8.jpg)
1992: First ICU Rotation
J Crit Care (1994) 9: 124-133
Reduced haemodynamic
variability compared to standard care
![Page 9: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/9.jpg)
PAC - Clinical Trials
• Shoemaker 1988
![Page 10: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/10.jpg)
PAC - Clinical Trials
• Intensive Care 1988-2006
• ARDS
• General ICU
• High Risk Surgery
• 12 Prospective RCT
![Page 11: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/11.jpg)
PAC - Clinical Trials• Evaluated different targets
• CO / Oxygen Delivery (explicit) or Physician determined
• +/- MAP, Urine output, skin changes
• Used different guidance (rules)
• CVP and PAOP (explicit) or Physician determined
• Applied different therapy
• Fluids (crystalloids/colloids or RBC)
• Drugs (inotropes or pressors)
![Page 12: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/12.jpg)
PAC - Clinical Trials
• Intensive Care 1988-2006
• ARDS
• General ICU
• High Risk Surgery
• 12 Prospective RCT
![Page 13: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/13.jpg)
PAC - Clinical Trials• Various approaches to
haemodynamic care in numerous patient populations using either....
• explicit targeting of cardiac output / oxygen delivery
• guiding care based on perceived needs
does not improve outcome in a number of high risk patient groups
![Page 14: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/14.jpg)
Where does that leave us ?
![Page 15: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/15.jpg)
Drug Trials
Text
Annane D. Lancet 2007
![Page 16: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/16.jpg)
Drug Trials
Myburgh J. ICM 2008
![Page 17: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/17.jpg)
Drug Trials
Text
De Becker D. NEJM 2010
![Page 18: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/18.jpg)
Fluids - Obsevational
• ARDS Clinical Trial Network, NEJM 2006
Outcome Conservative Strategy Liberal Strategy P Value
Death at 60 days (%) 25.5 28.4 0.30
Ventilator-free days from day 1 to day 28
14.6 ± 0.5 12.1 ± 0.5 <0.001
ICU-free days Days 1 to 7 Days 1 to 28
0.9 ± 0.113.4 ± 0.4
0.6 ± 0.111.2 ± 0.4
<0.001<0.001
Organ-failure-free days Days 1 to 7 Cardiovascular failure CNS failure Renal failure Hepatic failure Coagulation abnormalities Days 1 to 28 Cardiovascular failure CNS failure Renal failure Hepatic failure Coagulation abnormalities
3.9 ± 0.13.4 ± 0.25.5 ± 0.15.7 ± 0.15.6 ± 0.1
19.0 ± 0.518.8 ± 0.521.5 ± 0.522.0 ± 0.422.0 ± 0.4
4.2 ± 0.12.9 ± 0.25.6 ± 0.15.5 ± 0.15.4 ± 0.1
19.1 ± 0.417.2 ± 0.521.2 ± 0.521.2 ± 0.521.5 ± 0.4
0.040.020.450.120.23
0.850.030.590.180.37
Dialysis to day 60 Patients (%) 10 14 0.06
Days 11.0 ± 1.7 10.9 ± 1.4 0.96
Liberal fluids
associated with
increased ICU and
ventilator time and
no reduction in renal failure
![Page 19: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/19.jpg)
Fluids - Observational
After correcting for age and APACHE II, positive fluid balance correlated with increased mortality
Boyd J.H.et al Crit Care Med 2011
![Page 20: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/20.jpg)
Fluids - Recommendations
CCM Feb 2011
![Page 21: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/21.jpg)
Currently
Low Blood Pressure
Low Cardiac Output
Organ Failure Vasopressors
Inotropes
Fluids
![Page 22: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/22.jpg)
Currently
Low Blood Pressure
Low Cardiac Output
Organ Failure Vasopressors
Inotropes
Fluids
![Page 23: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/23.jpg)
The Future ??• Each decade we reject a new
haemodynamic variable, on which, to base interventions
• 1980: PAWP
• 1990: VO2-DO2 relationship
• 2000: LVEDV GEDVI
• 2010: Forget about monitoring - just ECHO everything (over and over)
![Page 24: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/24.jpg)
Where does that leave us ?
![Page 25: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/25.jpg)
Where does that leave us ?• Prescriptive Approaches
• RELIEF (Restrictive versus Liberal Fluid Therapy in Major Abdominal Surgery)
• Clinical Trials.gov Id: NCT 01424150
• Random allocation of drugs
• Targeting Fluid Balance
![Page 26: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/26.jpg)
A Physiological Approach• Instead of targeting MAP or CO/O2D
indices
• using DEPENDENT circulatory variables (e.g. CVP, EDV, PPV) to guide therapy
• Target BOTH simultaneously using
• INDEPENDENT circulatory variables
- Volume state
- Cardiac function
- Systemic vascular resistance
![Page 27: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/27.jpg)
Mean Systemic Filling Pressure
![Page 28: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/28.jpg)
Mean Systemic Filling Pressure
Anaesthesia2009(64):1218-
1228
![Page 29: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/29.jpg)
Mean Systemic Filling Pressure
• Allows independent assessment of volume state
and
• Allows independent assessment of cardiac function
![Page 30: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/30.jpg)
Modelling the circulation
![Page 31: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/31.jpg)
Stay with me.......
![Page 32: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/32.jpg)
MSFP(modeled)
CO
Press av MSFP
![Page 33: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/33.jpg)
Venous compliance lower than assumed
CO
Press av MSFP
![Page 34: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/34.jpg)
Venous compliance higher than assummed
CO
Press av
![Page 35: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/35.jpg)
Independent variables of the circulation
• MSFP = Volume state= 0.96(CVP) + 0.04(MAP) + c(CO)
• HP (Heart Performance) = Inotropy state
=(MSFP - RAP) / MSFP
• SVR = Arteriolar tone stateThese are the numerical descriptors (indicators) of the
circulation
![Page 36: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/36.jpg)
Choosing the Target
• Cardiac output
• Mean arterial pressure
• (Cardiac Power = CO x MAP)
• Captures both kinetic and potential energy of the circulation
• Allows assessment of volume responsiveness
![Page 37: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/37.jpg)
Cardiogenic Shock
• Cardiac Power
![Page 38: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/38.jpg)
Cardiogenic Shock
• Cardiac Power
![Page 39: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/39.jpg)
Navigator GuidanceHeart efficiency axis Mean systemic
filling pressure axisData from Monitors
Targets set by clinician
Main menuarea
Data linkStatus area
Target zone
Systemicresistance axis
Patient’s current position
Arrow shows next therapeutic direction
Other data
![Page 40: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/40.jpg)
Intended Control: Following the arrow• Vertical Axis Control
• If Cardiac Power Low: increase MSFP or Inotropy (depending on HP)
• If Cardiac Power High: decrease MSFP or Inotropy* (depending on HP)
• Horizantal Axis Control
• If Cardiac Power is not well “geared” (SVR too high or too low): dilators and constrictors
![Page 41: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/41.jpg)
Cardiac Power Relevance
![Page 42: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/42.jpg)
Navigator Screens: NAV-1
Intervention(Treatment compliance not required)
Control
![Page 43: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/43.jpg)
What we learned• Even if you know the independent
determinants of circulatory variables (like CO)......
• Even if you use them to direct therapy to a meaningful target (like cardiac power).....
• You don’t necessarily know when you should change the target and when you should change the treatments
![Page 44: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/44.jpg)
Structured approach to circulatory care using
Navigator
Determine TargetsDefine (allowable)
interventions
Targets attained andmaintained (ASD < 1.5)within intervention limits
Targets not maintained within intervention limits (ASD >1.5)
New InterventionNew Target
+1. Medicalassessment
2. Nursingassessment
or3. Continual maintenance No change
![Page 45: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/45.jpg)
Circulatory Targeting Sheet
Volume resuscitation Colloids = 0 Colloids = < 1000 mls Colloids = < 2000ms
Vasopressor requirements Noradren = 0 Noradren = 1 - 10 Noradren = >10
AVP = 0 AVP = 1/hr AVP 2/hr
Vasodilator requirements GTN = 0 GTN =20 or more GTN ___ - ___
SNP 10 - 50 SNP 50 - 150 SNP ___ - ___
Inotrope requirements Adren: = 0 Adren: < 5 Adren: 5- ___
Milrinone = 0 Milrinone = 5 Milrinone = 5 - 20
MAP
Card Index
ScvO2 > 70
Heart Rate
HP inotrope trigger
HP medical review trigger
![Page 46: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/46.jpg)
Improving Circulatory Care .....
• Further investigations into physiologically based treatments
• Cannot accept that understanding the circulation can’t lead to improved care
![Page 47: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/47.jpg)
Outcomes of cardiogenic shock (CS) complicating acute coronary
syndromes/myocardial infarction
![Page 48: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/48.jpg)
Outcomes of cardiogenic shock (CS) complicating acute coronary
syndromes/myocardial infarction
![Page 49: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/49.jpg)
Outcomes
![Page 50: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/50.jpg)
•High early mortality (despite early intervention)•Difficult to support medically•Reasonable quality of life post•Not invariably associated with irrecoverable myocardial damage
Cardiogenic Shock Outcomes
![Page 51: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/51.jpg)
Krischan D. Sjauw European Heart Journal
(2009) 30, 459–468
IABP
![Page 52: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/52.jpg)
Unverzagt S Cochrane
Library 2011
IABP
![Page 53: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/53.jpg)
•Ongoing Trials•IABP Shock II;•RECOVER II Trial
•Planned Recruitment•984
IABP
![Page 54: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/54.jpg)
Elmir Omerovic Vascular Health and Risk
Management 2010:6 657–663
Inotropes
![Page 55: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/55.jpg)
![Page 56: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/56.jpg)
• Extra Corporeal Membrane Oxygenation is a form of extracorporeal life support where an external artificial circuit carries venous blood from the patient to a gas exchange device (oxygenator) where blood becomes enriched with oxygen and has carbon dioxide removed. This blood then re-enters the patient circulation
• Veno-arterial ECMO– Percutaneous
cardiopulmonary support (bypass)
ECMO
![Page 57: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/57.jpg)
return
access
![Page 58: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/58.jpg)
Day 2-3Lymphocytic myocarditis
What’s possible
![Page 59: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/59.jpg)
What’s possible……
Day 10
Day 5
![Page 60: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/60.jpg)
![Page 61: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/61.jpg)
![Page 62: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/62.jpg)
![Page 63: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/63.jpg)
![Page 64: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/64.jpg)
![Page 65: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/65.jpg)
Christian A. Bermudez Ann Thorac Surg 2011;92:2125–31
![Page 66: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/66.jpg)
Diagnostic Group
Number(168)
Age(43)
ECMO Days (7.3)
SW SB NW Alive Discharge
CM/FM40 42 7.8 21 14 5 27(+3)
(75%)
Heart Tx (0-7) 46 51 6.6 43 1 2* 33 (72%)
AMI25 52.4 9.1 12 8 5 14 (56%)
Heart Tx (late) 10 44 11.9 4 3 3 3 (30%)
Septic Shock 7 38 4.9 3 0 4 2 (29%)
ECMO for Cardiac Failure 2003-2012
![Page 67: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/67.jpg)
•25 patients (2003-2012)•Average Age: 52.4•Average Days on Support: 9.14•56% Survival to hospital discharge•5 NW•8 SB•12 SW
Alfred CS-AMI
![Page 68: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/68.jpg)
•Veno-arterial ECMO•Centrifugal VAD•Tandem Heart LVAD
•RVAD, LVAD, BiVAD
•Impella Recover•B2B (Bridge to Bridge)•Long term VAD
Current Mechanical Treatment Options for
Severe Acute Heart Failure
![Page 69: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/69.jpg)
![Page 70: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/70.jpg)
Ischaemic C/M60 month
mortality 50%
Non-Ischaemic C/M
60 month mortality 35%
![Page 71: VIN 2012 - Pellegrino on ECMO](https://reader038.vdocuments.us/reader038/viewer/2022103016/554b8f93b4c9056d5f8b58a6/html5/thumbnails/71.jpg)
• Cardiogenic shock remains a challenging syndrome to treat but the early application of safe ECMO seems possible to provide major patient benefits
• Simple
• Transferable
Conclusion